JJP Biologics doses first RA patients in nebaprubart Phase 1b trial
JJP Biologics has dosed the first patients in a Phase 1b clinical trial evaluating nebaprubart, its investigational anti-CD89 monoclonal antibody, in seropositive rheumatoid arthritis. The Warsaw-based company said the move marks the second indication for the asset, following an ongoing Phase 1b study in linear IgA dermatosis (LAD) for which interim data were reported positively in June 2026.
Rheumatoid arthritis affects an estimated 18 million people globally and is characterised by chronic joint inflammation that can lead to irreversible structural damage. Biological disease-modifying antirheumatic drugs are well established, but a meaningful share of patients either fail to respond adequately, lose response over time, or discontinue because of side effects. JJP Biologics is targeting a subset of that unmet need: patients with seropositive disease, in whom IgA autoantibodies are thought to drive a more severe disease phenotype through activation of the CD89 receptor on myeloid effector cells.
The mechanism
Nebaprubart is an IgG4-kappa monoclonal antibody designed to selectively block CD89, the primary receptor through which IgA triggers myeloid-cell activation. The company argues that by interrupting this pathway upstream, nebaprubart can suppress the neutrophil-driven synovial inflammation and cartilage degradation associated with progressive RA without depleting circulating IgA or depleting immune cells. That reversibility is positioned as a differentiator relative to cell-depletion or immunoglobulin-reduction approaches.
The open-label Phase 1b trial will assess safety, tolerability, pharmacokinetics and immunogenicity, with exploratory endpoints covering disease activity and patient-reported outcomes. Trial details are registered on the EU Clinical Trials Information System under reference 2023-508661-33-00.
Chief executive Pawel Szczepanski said the first dosing "marks significant progress as we expand the clinical evaluation of our first-in-class anti-CD89 antagonist therapy into a second immune-driven indication." Chief medical officer Sohail Ahmed described the IgA/CD89 pathway as "a highly differentiated and scientifically compelling target with the potential to deliver meaningful benefits" for the substantial proportion of RA patients who remain inadequately controlled.
Robert Rupinski, a consultant rheumatologist at Rheuma Medicus Specialist Center in Poland, estimated that 30 to 40 per cent of RA patients fail to achieve an adequate response, with others losing response over time. He said it was "encouraging to see a novel modality being investigated."
Market context and competitive positioning
The CD89 pathway remains largely unaddressed by approved biologics, which predominantly target downstream cytokines such as TNF, IL-6 and IL-17, or deplete B cells via CD20. JJP Biologics claims first-mover advantage in clinical validation of the IgA/CD89 axis, and the LAD orphan designation it received from the European Commission in 2022 gives the company a degree of regulatory signal ahead of larger competitors.
That said, the RA treatment landscape is deeply competitive. Multiple JAK inhibitors, bispecifics and next-generation biologics are already approved or in late-stage development, and positioning a Phase 1b asset against them will require robust efficacy signals in Phase 2 and beyond. The broader IgA pathway is attracting growing interest across several autoimmune indications, including IgA nephropathy, lupus and inflammatory bowel disease, where a number of academic groups and early-stage companies are pursuing related but distinct approaches. If nebaprubart generates compelling pharmacodynamic data in RA and maintains the safety profile seen in LAD, JJP Biologics could attract partnership interest from larger pharmaceutical groups seeking differentiated immunology assets. For now, investors and clinicians will watch for Phase 1b safety readouts and any exploratory biomarker signals before drawing firmer conclusions about the asset's commercial trajectory.